Fanconi Anemia and Bone Marrow Failure: Transplant Timing, Sibling Donor Screening, Conditioning Regimen Adjustments, and Haploidentical Transplant Options for International Families, Caregivers, and Physicians Considering Care in China

What Is Fanconi Anemia, and Why Is Its Bone Marrow Failure Different?

Fanconi anemia (FA) is an inherited disorder of DNA repair, caused by mutations in one of more than twenty FANC genes. Most forms are inherited in an autosomal recessive pattern, meaning both parents typically carry one copy of a mutated gene without being affected themselves. Because the defect is present within the blood-forming stem cells themselves — not caused by an external immune attack — bone marrow failure in FA usually develops gradually, often beginning with mild, isolated cytopenias that worsen over months to years.

FA is also associated with a substantially elevated lifetime risk of myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML), as well as certain solid tumors later in life — particularly head and neck and gynecologic squamous cell carcinomas. Diagnosis is confirmed through a chromosome breakage test, which exposes a blood sample to agents such as diepoxybutane (DEB) or mitomycin C (MMC) and measures abnormal chromosome breakage characteristic of impaired DNA repair.

This combination — progressive marrow failure plus an intrinsic leukemia risk — is what makes transplant timing in FA a distinct clinical question, different from the decision framework used for acquired aplastic anemia, where immunosuppressive therapy is often a reasonable first step.

Why Transplant Timing Is a Central Decision in Fanconi Anemia

Unlike some other transplant indications, the question in FA is rarely whether transplant will eventually be needed — it usually will be. The more consequential question is when to proceed, because both transplanting too early and transplanting too late carry meaningful trade-offs.

Because of this balance, many specialist centers favor a proactive approach: planning for transplant once cytopenia reaches a defined threshold, or as soon as bone marrow surveillance detects early clonal changes — rather than waiting for severe aplastic anemia-level blood counts or confirmed MDS/AML. This is a meaningfully different approach from "watch and wait until it becomes an emergency," and is a key question for families to raise directly with their hematology team.

Why Standard Conditioning Regimens Must Be Adjusted for Fanconi Anemia

Standard myeloablative conditioning — higher-dose chemotherapy, sometimes combined with radiation — relies on the body's own DNA repair mechanisms to recover from treatment-related cellular damage. Because FA cells have an impaired capacity to repair DNA damage, standard conditioning intensity carries substantially higher toxicity risk in FA patients than in most other transplant candidates.

For this reason, transplant centers with FA experience use protocols specifically adjusted for this condition — typically built around fludarabine combined with low-dose cyclophosphamide, generally avoiding radiation where possible. Choosing a centre with specific, demonstrated experience conditioning FA patients — rather than applying a generic pediatric transplant protocol — is one of the most consequential decisions a family can make.

China's nationwide CCBMTR registry reports FA-specific outcomes consistent with this approach: a 3-year event-free survival of 79% with haploidentical donors versus 76% with other donor types, with fludarabine plus low-dose cyclophosphamide cited as the preferred conditioning approach. More detail on the underlying registry is available in our summary of 22,381 pediatric transplants in the CCBMTR registry. These are registry-level figures — individual outcomes depend on disease stage at transplant, donor selection, and conditioning protocol, and require review of a specific patient's records by a specialist team.

Why Haploidentical Transplant Is Particularly Relevant to the Timing Question

The proactive timing approach described above is only practical if a suitable donor can be identified without a lengthy delay. This is where donor availability and transplant timing intersect directly.

A parent is, biologically, a haploidentical (half-matched) donor for their child in essentially every case — and unlike a sibling, a parent does not need to be screened to rule out FA itself, since FA is not typically expressed in a heterozygous carrier parent. This means that once a family understands FA is present, a parent donor is almost immediately available for evaluation, without waiting on a registry search that can take three to six months. As haploidentical transplant protocols — including the Beijing Protocol developed in China — have matured, published FA outcomes using haploidentical donors have become broadly comparable to matched donor transplant at experienced centres, removing much of the historical rationale for delaying transplant while awaiting a fully matched donor.

This article is also part of ChinaMed Waypoint's pediatric leukemia and blood disorders resources for international families, given how closely FA transplant planning overlaps with broader pediatric donor-shortage decision-making.

What Ongoing Bone Marrow Surveillance Typically Involves

Because FA marrow failure and clonal evolution can progress gradually and without obvious symptoms, many specialist centers recommend regular bone marrow evaluation — typically including cytogenetic analysis — on an annual basis or more frequently once cytopenia becomes evident. This surveillance is intended to detect early warning signs, such as specific chromosomal changes associated with progression toward MDS, before they become clinically apparent through blood counts alone.

Supportive Care Before Transplant, and Life After Transplant

While cytopenia is being monitored and transplant is being planned, supportive care — transfusion management, infection precautions, and in some cases androgen therapy to temporarily support blood counts — forms an important part of care. Androgen therapy can help some patients for a period but does not address the underlying marrow failure and carries its own side effects, so it is generally used as a bridge rather than a long-term substitute for transplant.

At Chinese hematology centres, supportive care alongside standard treatment may also include integrative approaches such as acupuncture and Traditional Chinese Medicine for fatigue, sleep, and appetite support. These are positioned as complementary to — never as a replacement for — transfusion support, conditioning, or transplant itself.

It is also important for families to understand that a successful transplant resolves the bone marrow failure and the leukemia risk arising from the marrow, but does not correct the FA gene mutation elsewhere in the body. Lifelong surveillance for FA-associated solid tumors — particularly head and neck and gynecologic squamous cell carcinomas — remains necessary after transplant.

See the supportive care and Traditional Chinese Medicine resources for more on what integrative supportive care during hematology treatment in China may involve.